4.7 Review

Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?

Journal

PHARMACEUTICS
Volume 14, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14081599

Keywords

antifibrotic strategies; cardiac fibrosis; cardiovascular diseases; fibrosis pathways; therapeutic strategies

Funding

  1. Romanian Ministry of Education and Research, CNCS-UEFISCDI within PNCDI III [PN-III-P1-1.1-TE-2019-0370]

Ask authors/readers for more resources

This paper provides a comprehensive review of cardiac fibrosis, including its pathophysiological pathways, its role in cardiovascular diseases, and potential therapeutic strategies. It also highlights unanswered questions and identifies areas for future research.
Fibrosis, characterized by an excessive accumulation of extracellular matrix, has long been seen as an adaptive process that contributes to tissue healing and regeneration. More recently, however, cardiac fibrosis has been shown to be a central element in many cardiovascular diseases (CVDs), contributing to the alteration of cardiac electrical and mechanical functions in a wide range of clinical settings. This paper aims to provide a comprehensive review of cardiac fibrosis, with a focus on the main pathophysiological pathways involved in its onset and progression, its role in various cardiovascular conditions, and on the potential of currently available and emerging therapeutic strategies to counteract the development and/or progression of fibrosis in CVDs. We also emphasize a number of questions that remain to be answered, and we identify hotspots for future research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available